Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized extended-interval natalizumab dosing in relapsing-remitting multiple sclerosis
2019-002566-13Phase 4Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS) and multiple sclerosis (MS), sponsored by Amsterdam University Medical Center. Primary endpoint: Radiological disease activity. Started Oct 2019; status: active.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)multiple sclerosis (MS)
Beyond the preview
Go deeper on 2019-002566-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002566-13.